RCAG
JSPR icon

Rehmann Capital Advisory Group’s Jasper Therapeutics JSPR Stock Holding History

Rehmann Capital Advisory Group’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.44K Hold
15,300
– – ﹤0.01% 702
2026
Q1 		$13.4K Buy
+15,300
New +$21.2K ﹤0.01% 676

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rehmann Capital Advisory Group's JSPR Position: Q2 2026 in Review

Rehmann Capital Advisory Group held its Jasper Therapeutics (JSPR) position steady in Q2 2026 at 15,300 shares worth $6.44K. The position accounts for ﹤0.01% of the portfolio, ranked #702.

Rehmann Capital Advisory Group first reported a position in JSPR in Q1 2026 and has held it in 2 quarters since. The position peaked at $13.4K in Q1 2026. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Rehmann Capital Advisory Group held 15,300 shares of Jasper Therapeutics worth $6.44K as of Q2 2026.
  • Rehmann Capital Advisory Group left its Jasper Therapeutics share count unchanged in Q2 2026.
  • Jasper Therapeutics made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q2 2026, its #702 holding.
  • Rehmann Capital Advisory Group first reported a position in Jasper Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Rehmann Capital Advisory Group's Jasper Therapeutics position peaked at $13.4K in Q1 2026.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q2 2026, filed 20 Aug 2026.